Development of angiogenesis inhibitors for clinical applications
- 1 November 1990
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 11 (11) , 457-461
- https://doi.org/10.1016/0165-6147(90)90127-t
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Transforming growth factor-beta (TGFβ) is chemotactic for human monocytes and induces their expression of angiogenic activityPublished by Elsevier ,2005
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivoBiochemical and Biophysical Research Communications, 1989
- Complete resolution of Kaposi's sarcoma with systemic etretinate therapy in a patient with mycosis fungoidesJournal of the American Academy of Dermatology, 1989
- Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2aNew England Journal of Medicine, 1989
- Biological and chemical characterization of basic FGF-saporin mitotoxinBiochemical and Biophysical Research Communications, 1989
- Neovascularisation and its role in the osteoarthritic process.Annals of the Rheumatic Diseases, 1988
- Angiogenesis and the skinJournal of the American Academy of Dermatology, 1987
- Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantreneBiochemical and Biophysical Research Communications, 1986
- Partial purification of a 5.7K glycoprotein from bovine vitreous which inhibits both angiogenesis and collagenase activityBiochemical and Biophysical Research Communications, 1985